RSV, Canada and GSK

GSK RSV vaccine approved in Canada for adults aged 50-59 at increased risk
Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada for the prevention of lower respiratory tract disease (LRTD) caused
Canada approves Moderna's RSV vaccine for those age 60 and older, company says
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years and older, making it the country's first authorized mRNA-based shot for the condition.
Canada approves GSK's RSV vaccine for adults aged 50 to 59
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot for that age group.
Moderna receives Health Canada approval for RSV vaccine for 60 years, older
Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease
Health Canada approves Moderna's mRNA RSV vaccine, company says
Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older.
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years and older, making it the country's first authorised mRNA-based shot for the condition.
Hosted on MSN12d
New RSV vaccine distribution: Who's at the top of the list?
This summer, the FDA approved Moderna's mRESVIA RSV vaccine for adults. Last year, the FDA approved Abrysvo (Pfizer) and ...
FiercePharma12d
GSK tries to steady the ship as Arexvy sales plummet in wake of CDC guidance changes
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...
infectiousdiseaseadvisor.com7d
Arexvy Looks Promising for RSV Protection in Younger At-Risk and Immunocompromised Adults
Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.
STAT11d
Sales of GSK’s RSV vaccine down dramatically from last year
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
Doctors stress the importance of the RSV vaccine
With cold and flu season around the corner, Doctors recommend receiving the RSV vaccine ahead of the holidays.
BioPharma Dive11d
GSK vaccine sales sink on lower demand for RSV, shingles shots
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
Everything You Need To Know About RSV This Fall
RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...
Yahoo Finance5d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59
GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 ...
Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...